Tirzepatide for Psoriasis and Obesity

Recruiting at 37 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Recruiting

Sponsor: Eli Lilly and Company

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.

Research Team

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Principal Investigator

Eli Lilly and Company

Eligibility Criteria

This trial is for people with moderate-to-severe plaque psoriasis (PsO) who are also overweight or obese, and have at least one weight-related health issue. It's not clear what the specific exclusions are, but typically they would include certain medical conditions or treatments that could interfere with the study.

Inclusion Criteria

I started treatment with ixekizumab about 2-4 months ago.

I have been diagnosed with moderate-to-severe plaque psoriasis.

My BMI is over 27 and I have a weight-related health issue, or it's over 30.

Exclusion Criteria

Are currently enrolled in any other clinical study

Have a known hypersensitivity to tirzepatide or to any of its components

I have had pancreatitis before the first visit.

Treatment Details

Interventions

• Tirzepatide (Other)

Trial Overview The trial is testing if adding a drug called Tirzepatide to another medication named Ixekizumab helps patients with PsO and obesity better than Ixekizumab alone. The study will observe participants for up to one year in a real-world clinical setting.

Participant Groups

Group I: Tirzepatide Experimental Treatment 1 Intervention

Participants will continue to receive ixekizumab and take tirzepatide subcutaneously (SC) as per label.

Who Is Running the Clinical Trial?

Eli Lilly and Company

Lead Sponsor

Trials

2,708

Recruited

3,720,000+

Dr. Daniel Skovronsky

Eli Lilly and Company

Chief Medical Officer since 2018

MD from Harvard Medical School

David A. Ricks

Eli Lilly and Company

Chief Executive Officer since 2017

BSc from Purdue University, MBA from Indiana University